Form 4: AIM ImmunoTech CEO Thomas Equels Increases Stake in Company
SEC Form 4 Filing
AIM ImmunoTech's CEO, Thomas K Equels, recently purchased 5,000 shares of the company's common stock at a price of $0.303 per share.
Summary
- On September 16, 2024, Thomas K Equels, the CEO and President of AIM ImmunoTech Inc., acquired 5,000 shares of common stock.
- The shares were purchased at a price of $0.303 per share.
- Following this transaction, Equels directly owns 1,493,042 shares of AIM ImmunoTech Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase indicates confidence, but it's a relatively small transaction.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of stock purchase by Thomas K Equels |
| 09/17/2024 | Date of Form 4 filing |
Keywords
AIM ImmunoTech, Thomas Equels, insider trading, Form 4, stock purchase, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.